Status:
UNKNOWN
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Renal Failure
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membra...
Eligibility Criteria
Inclusion
- diagnosis of coronary heart disease including stable angina, unstable angina, acute myocardial infarction
- taking dual antiplatelet drugs (clopidogrel 75mg qd + aspirin 100mg qd or ticagrelor 90 mg,bid + aspirin 100 mg,qd) at least 5 days
- haemodialysis patients
- sign informed consent
Exclusion
- platelet count\>450 × 10 9 /L or \<100 × 10 9 /L
- using IIb / IIIa inhibitor drugs within 10days
- taking nonsteroidal anti-inflammatory drugs other than aspirin
- hemorrhagic disease
- allergic to aspirin, ticagrelor or clopidogrel
- other factors may affect the results of this study
Key Trial Info
Start Date :
November 10 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03330223
Start Date
November 10 2017
End Date
September 1 2019
Last Update
January 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029